Back to top

Design Therapeutics reports Q2 EPS (32c), consensus (34c)

“Design continued its strong operational execution in the second quarter building on the positive RESTORE-FA data reported in May. Those four-week ...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Design Therapeutics, Inc. (DSGN)